Yonsei Med J.  2005 Feb;46(1):104-111. 10.3349/ymj.2005.46.1.104.

Clinical Characteristics of Dialysis Related Sclerosing Encapsulating Peritonitis: Multi-center Experience in Korea

• Kim BS
• Choi HY
• Ryu DR
• Yoo TH
• Park HC
• Kang SW
• Choi KH
• Ha SK
• Han DS
• Lee HY

• KMID: 2158119
• DOI: http://doi.org/10.3349/ymj.2005.46.1.104

Abstract

Sclerosing encapsulating peritonitis (SEP) is a rare but serious complication in patients with continuous ambulatory peritoneal dialysis (CAPD), and is characterized by a progressive, intra-abdominal, inflammatory process resulting in the formation of sheets of new fibrous tissue, which cover, bind, and constrict the viscera, thereby compromising the motility of the bowel. No satisfactory estimate is available on the comparative incidence of dialysis related SEP and the pathogenesis of SEP still remains uncertain. Although recent therapeutic approaches have reported varying degrees of success, an efficient measure to detect, at an early stage, patients at risk for SEP would be beneficial and a standardized treatment regimen to prevent the illness is urgently needed. This study aimed to evaluate the clinical features of SEP and to identify the possible risk factors for the development of SEP in CAPD patients. We retrospectively reviewed by questionnaire SEP cases among CAPD patients from 7 university hospital dialysis centers in Korea, including Yonsei University, Ajou University, Catholic University, Inha University, Kyungpook University, Seoul National University and Soonchunhyang University, from January 1981 to December 2002. Out of a total of 4, 290 CAPD patients in these centers, 34 cases developed SEP with an overall prevalence of 0.79%. The male to female ratio was 17: 17. The median age of these patients was 44.5 years (range 19 - 66). The median duration of CAPD before SEP was 64 months (9 - 144) and 68% of patients (23/34) had been on CAPD for more than 4 years. Peritonitis (including two fungal cases) was the main cause of catheter removal in SEP (27 cases, 79%). Seventy-five percent of the cases (15/ 20) were administered beta-blocker for a mean duration of 85 months (26 - 130). Among 10 cases with available peritoneal equilibration test (PET) data, 8 showed high transporter characteristics, and the remaining 2 were high average. Eighteen cases were diagnosed by clinical and radiologic methods, and 16 were surgically diagnosed. Eleven cases were surgically treated and the others were treated conservatively with intermittent total parenteral nutrition (TPN). The overall mortality rate was 24%. SEP is a serious, life threatening complication of CAPD. Most cases had a PD duration of more than 4 years, a history of severe peritonitis, and high transporter characteristics in PET. Therefore, to reduce the incidence of SEP, careful monitoring and treatment, including early catheter removal in patients with severe peritonitis, should be considered for long-term CAPD patients with the above characteristics.

Keyword

Sclerosing encapsulating peritonitis; long-term CAPD; peritonitis

MeSH Terms

Adult
Aged
Female
Humans
Incidence
Korea/epidemiology
Male
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects/*statistics & numerical data
Peritonitis/*epidemiology/etiology/*pathology
Prevalence
Sclerosis

Figure

• 

  Fig. 1 Distribution of sclerosing encapsulating peritonitis (SEP) cases according to CAPD duration (N=34). SEP was commonly noted in the patients with CAPD duration of more than 4 years.

Reference

1. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med. 1980. 140:1201–1203.

2. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant. 1988. 3:66–69.

3. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int. 1992. 12:14–27.

4. Cox SV, Lai J, Suranyi M, Walker N. Sclerosing peritonitis with gross peritoneal calcification: a case report. Am J Kidney Dis. 1992. 20:637–642.

5. Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif. 1989. 7:95–108.

6. Trivedi H, Khanna R, Lo WK, Prowant BF, Nolph KD. Reproducibility of the peritoneal equilibration test in CAPD patients. Asaio J. 1994. 40:M892–M895.

7. Marichal JF, Faller B, Brignon P, Wagner D, Straub P. Progressive calcifying peritonitis: a new complication of CAPD? Report of two cases. Nephron. 1987. 45:229–232.

8. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis. 1996. 28:420–427.

9. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant. 1998. 13:154–159.

10. Afthentopoulos IE, Passadakis P, Oreopoulos DG, Bargman J. Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. Adv Ren Replace Ther. 1998. 5:157–167.

11. Garosi G, Di Paolo N. Peritoneal sclerosis: one or two nosological entities? Semin Dial. 2000. 13:297–308.

12. Oreopoulos DG, Khanna R, Wu G. Sclerosing obstructive peritonitis after CAPD. Lancet. 1983. 2:409.

13. Di Paolo N, Garosi G. Peritoneal sclerosis. J Nephrol. 1999. 12:347–361.

14. Holland P. Sclerosing encapsulating peritonitis in chronic ambulatory peritoneal dialysis. Clin Radiol. 1990. 41:19–23.

15. Ing TS, Daugirdas JT, Gandhi VC. Peritoneal sclerosis in peritoneal dialysis patients. Am J Nephrol. 1984. 4:173–176.

16. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol. 1987. 57:239–247.

17. Selgas R, Bajo MA, Del Peso G, Jimenez C. Preserving the peritoneal dialysis membrane in long-term peritoneal dialysis patients. Semin Dial. 1995. 8:326–332.

18. Krediet RT. Advances in peritoneal dialysis: towards improved efficacy and safety. Blood Purif. 1998. 16:1–14.

19. Marigold JH, Pounder RE, Pemberton J, Thompson RP. Propranolol, oxprenolol, and sclerosing peritonitis. Br Med J. 1982. 284:870.

20. Myllarniemi H, Leppaniemi A. Peritoneal fibrosis due to practolol. Scanning electron microscopical and histological observations. Acta Chir Scand. 1981. 147:137–142.

21. Nicholls JT, Rutty DA. Sclerosing peritonitis with short-term propranolol therapy. Arch Intern Med. 1980. 140:1124–1125.

22. Eisenberg ES, Alpert BE, Weiss RA, Mittman N, Soeiro R. Rhodotorula rubra peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Am J Med. 1983. 75:349–352.

23. Flanigan M, Anderson D, Freeman RM. Peritoneal dialysis complicated by fungal peritonitis and peritoneal fibrosis. Am J Med. 1984. 76:A113. A125.

24. Tzamaloukas AH. Peritonitis in peritoneal dialysis patients: an overview. Adv Ren Replace Ther. 1996. 3:232–236.

25. Chew CG, Clarkson AR, Faull RJ. Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. Nephrol Dial Transplant. 1997. 12:821–822.

26. Verger C, Brunschvicg O, Le Charpentier Y, Lavergne A, Vantelon J. Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis. Proc EDTA. 1981. 18:199–205.

27. Baron MA. Structure of the intestinal peritoneum in man. Am J Anat. 1941. 69:439–496.

28. Jorres A, Gahl GM, Frei U. Peritoneal dialysis fluid biocompatibility: Does it really matter? Kidney Int Suppl. 1994. 48:S79–S86.

29. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial. 1993. 9:187–189.

30. Charney DI, Gouge SF. Chemical peritonitis secondary to intraperitoneal vancomycin. Am J Kidney Dis. 1991. 17:76–79.

31. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis. 1994. 24:819–825.

32. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000. 20:Suppl 4. S43–S55.

33. Perez-Fontan FJ, Soler R, Sanchez J, Iglesias P, Sanjurjo P, Ruiz J. Retractile mesenteritis involving the colon: barium enema, sonographic, and CT findings. AJR Am J Roentgenol. 1986. 147:937–940.

34. Celicout B, Levard H, Hay J, Msika S, Fingerhut A, Pelissier E. French Associations for Surgical Research. Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. Dig Surg. 1998. 15:697–702.

35. Genereau T, Bellin MF, Wechsler B, Le TH, Bellanger J, Grellet J, et al. Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Dig Dis Sci. 1996. 41:684–688.

36. Eltringham WK, Espiner HJ, Windsor CW, Griffiths DA, Davies JD, Baddeley H, et al. Sclerosing peritonitis due to practolol: a report on 9 cases and their surgical management. Br J Surg. 1977. 64:229–235.

37. Assalia A, Schein M, Hashmonai M. Problems in the surgical management of sclerosing encapsulating peritonitis. Isr J Med Sci. 1993. 29:686–688.

38. Jackson BT. Surgical treatment of sclerosing peritonitis caused by practolol. Br J Surg. 1977. 64:255–257.

39. Kittur DS, Korpe SW, Raytch RE, Smith GW. Surgical aspects of sclerosing encapsulating peritonitis. Arch Surg. 1990. 125:1626–1628.